Biohaven (NYSE:BHVN) Shares Rise 10.5%

Analysts Remain Bullish on Biohaven's Prospects

Apr. 1, 2026 at 5:56pm

Got story updates? Submit your updates here. ›

Biohaven Ltd. (NYSE:BHVN), a clinical-stage biopharmaceutical company focused on neurological and neurovascular diseases, saw its share price jump 10.5% during mid-day trading on Wednesday. The stock traded as high as $9.33 before closing at $9.3450, with 707,655 shares changing hands.

Why it matters

Biohaven's stock price increase comes amid ongoing analyst optimism about the company's prospects, with several firms maintaining 'Buy' ratings and boosting their price targets. The company's focus on developing therapies for high-unmet medical needs in the neurological space has generated significant investor interest.

The details

A number of equities research analysts have recently weighed in on Biohaven, with Citigroup reiterating a 'Buy' rating, Royal Bank of Canada boosting its target price to $23.00, and Raymond James Financial reaffirming a 'Strong Buy' rating. The company's debt-to-equity ratio stands at 4.59, with a quick and current ratio of 3.18.

  • Biohaven's share price shot up 10.5% during mid-day trading on Wednesday, April 1, 2026.

The players

Biohaven Ltd.

A clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases, headquartered in New Haven, Connecticut.

Citigroup

A global investment bank that reiterated a 'Buy' rating on Biohaven's stock.

Royal Bank of Canada

A multinational financial services company that boosted its price target for Biohaven to $23.00.

Raymond James Financial

A diversified financial services company that reaffirmed a 'Strong Buy' rating on Biohaven's stock.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Biohaven's upcoming financial results and any further updates on the company's pipeline of neurological therapies.

The takeaway

Biohaven's stock price surge reflects the ongoing investor optimism surrounding the company's potential to address high-unmet medical needs in the neurological space. The continued analyst support and positive sentiment suggest the stock may have further upside potential.